CompletedNCT02847130
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Studying B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- L. Lee DupuisChildren's Oncology Group
- Intervention
- Informational Intervention(other)
- Enrollment
- 530 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2016 – 2023
Study locations (30)
- Kaiser Permanente-Oakland, Oakland, California, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
- Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States
- Nemours Children's Hospital, Orlando, Florida, United States
- Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States
- Tampa General Hospital, Tampa, Florida, United States
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
- Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
- Blank Children's Hospital, Des Moines, Iowa, United States
- Children's Hospital New Orleans, New Orleans, Louisiana, United States
- Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States
- Bronson Methodist Hospital, Kalamazoo, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02847130 on ClinicalTrials.govOther trials for B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07133997Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaCity of Hope Medical Center
- RECRUITINGPHASE1NCT07361224Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.Tel-Aviv Sourasky Medical Center
- RECRUITINGPHASE2NCT07523737Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaBeijing Tongren Hospital
- RECRUITINGPHASE1, PHASE2NCT07283679Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07135466A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell MalignanciesSheba Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07480850Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGNCT07480837Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT07376642A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaSuzhou Immunofoco Biotechnology Co., Ltd